2001 · FINDING
Heffernan et al. — mouse adipose
AOD-9604 reduced adipose tissue mass in obese mice without affecting IGF-1.
⚠ RESEARCH USE ONLY · NOT FDA-APPROVED FOR HUMAN USE · NOT MEDICAL ADVICE
WEIGHT LOSSRESEARCH
AOD-9604.
HGH fragment that targets fat — without the growth signal
AKA · HGH Fragment 176-191 · Lipolytic Fragment
WEIGHT LOSSSUBCUTANEOUS
The C-terminal fragment of human GH (residues 176–191) plus a tyrosine cap. It keeps the lipolytic activity of GH while shedding the growth and glucose effects. Human trials have been mixed.
~30 minutes
Half-life
3
Citations
1
Routes
1
Categories
65
Popularity
AT A GLANCE.
§ 01 · TL;DRTHE QUICK READ.
The C-terminal fragment of human GH (residues 176–191) plus a tyrosine cap. It keeps the lipolytic activity of GH while shedding the growth and glucose effects. Human trials have been mixed.
Normal growth hormone does two things: grow tissue and break down fat. AOD-9604 is a fragment that only does the fat-breakdown part.
Fasted AM dosing most common. 8–12 week cycles.
WHAT IT MIGHT HELP WITH.
1
Increased lipolysis (fat breakdown)
2
No effect on IGF-1 or blood glucose
3
Stimulates cartilage regeneration (secondary finding)
4
Investigated for osteoarthritis
5
No growth of tissues — avoids acromegalic concerns
HOW IT WORKS.
§ 02 · MECHANISMNormal growth hormone does two things: grow tissue and break down fat. AOD-9604 is a fragment that only does the fat-breakdown part.
A 16-residue synthetic peptide representing the lipolytic domain of hGH. Acts on β3-adrenergic receptor signaling and mitochondrial fat oxidation pathways without activating GH receptor or IGF-1 axis.
WHO IT'S FOR
- ✓Researchers studying lipolysis
- ✓Fat-loss protocols without GH elevation
WHO SHOULD AVOID
- ✕Pregnancy
- ✕Anyone on thyroid medications without consultation
THE RESEARCH.
§ 03 · 3 STUDIES2007 · FINDING
Ng & Bornstein — clinical trial
N=534, 12-week human trial: modest weight reduction (~1.3kg vs. placebo), no blood glucose impact.
2013 · FINDING
Kwon et al. — cartilage
Accelerated cartilage healing in animal osteoarthritis model.
DOSING PROTOCOL.
§ 04 · DOSINGTYPICAL RANGE
Fasted AM dosing most common. 8–12 week cycles.
300mcg subcutaneous daily (reported research range)
FREQUENCY
Most-cited schedule
Once daily, empty stomach
ROUTES
Delivery methods
SUBCUTANEOUS
HALF-LIFE
Steady state drives frequency
~30 minutes
⚠ NOTE
These are reported protocols from research literature and practitioner accounts, not prescriptions. No FDA-approved human dose exists for research compounds. Anyone using AOD-9604 should work with a qualified physician and source from a supplier providing third-party COAs.
FORMS AVAILABLE
- · Lyophilized vial, 2mg or 5mg
⚠ RESEARCH INFORMATION ONLY · NOT MEDICAL ADVICE
SIDE EFFECTS & RISKS.
§ 06 · SAFETY·
Injection site reactions
Common · mild
·
Mild nausea
Occasional · mild
·
Headache
Occasional · mild
WHERE TO SOURCE
§ 07 · SUPPLIERPEAK LAB
PEPTIDES
PEPTIDES
SUPPLIER OF RECORD · 12 BATCHES PASSED
We tried nine suppliers across 2025 and kept picking PEAK LAB for AOD-9604: 99.4% HPLC purity, COA on every batch, cold chain intact. Shop through our link and we earn a small commission — affiliate relationship is disclosed.
◆ THE PEPGAINS DISPATCH
GET THE NEXT UPDATE FIRST.
New research on AOD-9604 + a weekly dispatch on everything else moving in the peptide world. One email. Unsubscribe in a click.